Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a report released on Monday. The brokerage issued a sell rating on the stock.

Several other research firms also recently issued reports on MBRX. Maxim Group dropped their price objective on Moleculin Biotech from $45.00 to $20.00 and set a buy rating on the stock in a report on Tuesday, March 26th. Roth Mkm reissued a buy rating and set a $40.00 price target on shares of Moleculin Biotech in a research report on Friday, April 12th.

Moleculin Biotech Stock Up 8.2 %

Shares of NASDAQ MBRX opened at $5.01 on Monday. Moleculin Biotech has a 1 year low of $4.28 and a 1 year high of $15.75. The stock’s 50-day simple moving average is $6.64 and its 200-day simple moving average is $8.02.

Institutional Trading of Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Atticus Wealth Management LLC bought a new position in Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 50,001 shares of the company’s stock, valued at approximately $43,000. Atticus Wealth Management LLC owned approximately 0.17% of Moleculin Biotech at the end of the most recent quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.